Finanzen von AbCellera Biologics Inc. (ABCL)ABCLAbCellera Biologics Inc.

AbCellera Biologics Inc. (ABCL) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Research fees, accounting for 98.5% of total sales, equivalent to $8.82M. Another important revenue stream is Licensing revenue. Understanding this composition is critical for investors evaluating how ABCL navigates market cycles within the Biotechnology & Medical Research industry.

Evaluating the bottom line, AbCellera Biologics Inc. maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -1399.43%, while the net margin is -1368.57%. These profitability ratios, combined with a Return on Equity (ROE) of -17.30%, provide a clear picture of how effectively ABCL converts its operational activities into shareholder value.

In the context of the broader market, ABCL competes directly with industry leaders such as RCUS and IOVA. With a market capitalization of $3.68B, it holds a significant position in the sector. When comparing efficiency, ABCL's gross margin of 100.00% stands against RCUS's 100.00% and IOVA's 46.54%. Such benchmarking helps identify whether AbCellera Biologics Inc. is trading at a premium or discount relative to its financial performance.

Abcellera's gross margin is consistently at 100%, showcasing strong revenue generation capabilities despite recent losses. The company has shown significant revenue growth, with a notable increase to $44.85 million in Q4 2025, compared to $4.65 million in Q4 2024.